<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9604648</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20305</journal-id>
<journal-id journal-id-type="nlm-ta">Nat Biotechnol</journal-id>
<journal-id journal-id-type="iso-abbrev">Nat. Biotechnol.</journal-id>
<journal-title-group>
<journal-title>Nature biotechnology</journal-title>
</journal-title-group>
<issn pub-type="ppub">1087-0156</issn>
<issn pub-type="epub">1546-1696</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28244991</article-id>
<article-id pub-id-type="pmc">6043900</article-id>
<article-id pub-id-type="doi">10.1038/nbt.3784</article-id>
<article-id pub-id-type="manuscript">NIHMS978761</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Oligonucleotide therapies for disorders of the nervous system</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Khorkova</surname>
<given-names>Olga</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wahlestedt</surname>
<given-names>Claes</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>OPKO Health Inc., Miramar, Florida, USA</aff>
<aff id="A2">
<label>2</label>Center for Therapeutic Innovation and the Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA</aff>
<author-notes>
<corresp id="FN1">Correspondence should be addressed to C.W. (<email>CWahlestedt@med.miami.edu</email>)</corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>COMPETING FINANCIAL INTERESTS</bold>
</p>
<p>The authors declare competing financial interests: details are available in the online version of the paper.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>30</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>27</day>
<month>2</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>3</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>13</day>
<month>7</month>
<year>2018</year>
</pub-date>
<volume>35</volume>
<issue>3</issue>
<fpage>249</fpage>
<lpage>263</lpage>
<!--elocation-id from pubmed: 10.1038/nbt.3784-->
<permissions>
<license license-type="permissions-link">
<license-p>Reprints and permissions information is available online at <ext-link ext-link-type="uri" xlink:href="http://www.nature.com/reprints/index.html">http://www.nature.com/reprints/index.html</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">Oligonucleotide therapies are currently experiencing a resurgence driven by advances in backbone chemistry and discoveries of novel therapeutic pathways that can be uniquely and efficiently modulated by the oligonucleotide drugs. A quarter of a century has passed since oligonucleotides were first applied in living mammalian brain to modulate gene expression. Despite challenges in delivery to the brain, multiple oligonucleotide-based compounds are now being developed for treatment of human brain disorders by direct delivery inside the blood brain barrier (BBB). Notably, the first new central nervous system (CNS)-targeted oligonucleotide-based drug (nusinersen/Spinraza) was approved by US Food and Drug Administration (FDA) in late 2016 and several other compounds are in advanced clinical trials. Human testing of brain-targeted oligonucleotides has highlighted unusual pharmacokinetic and pharmacodynamic properties of these compounds, including complex active uptake mechanisms, low systemic exposure, extremely long half-lives, accumulation and gradual release from subcellular depots. Further work on oligonucleotide uptake, development of formulations for delivery across the BBB and relevant disease biology studies are required for further optimization of the oligonucleotide drug development process for brain applications.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>